---
layout: default
title: Activated Charcoal Alcohol X-Ray Exposed Aluminum 
parent: 僅模型預測 (L5)
nav_order: 160
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Alcohol X-Ray Exposed Aluminum 
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Compound (15 Components): Insufficient Evidence for Repurposing Evaluation

## One-Sentence Summary

This submission describes a 15-ingredient compound whose components include activated charcoal, metals (gold, platinum, tin, tellurium), botanical extracts (Phytolacca americana root, Stillingia sylvatica root, Strychnos nux-vomica seed), and homeopathic-classified substances (Causticum, calcium sulfide, nitric acid). The composition pattern is consistent with a homeopathic multi-compound preparation, for which no original approved indication, no DrugBank identifier, and no regulatory license in Taiwan or the United States could be identified. The TxGNN model returned **no predicted indications** for this entry, and no supporting clinical trials or literature were retrievable for the compound as a whole.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available — no approved indication on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | Not applicable |
| Evidence Level | L5 — model prediction only, but even this is absent |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

This question cannot be answered in the conventional sense, because no repurposing prediction was generated.

The 15-component INN string contains substances characteristic of homeopathic formularies: Causticum (Hahnemann's potassium-based remedy), Phytolacca americana root (pokeweed), Strychnos nux-vomica seed (nux vomica), elemental metals in homeopathic potency (gold, platinum, tin, tellurium), and an unusual entry labeled "Alcohol, X-Ray Exposed." These ingredients, as listed, are not individually mapped to a single DrugBank record, and the compound as a whole has no DrugBank ID.

Because the TxGNN knowledge graph requires a valid DrugBank ID and a known indication to anchor its prediction, the model had no entry point for this compound. Without an anchored mechanism of action or a confirmed pharmacological target, the relational scoring that drives TxGNN predictions cannot run.

---

## Safety Considerations

No safety data — warnings, contraindications, or drug interaction records — were retrievable for this compound. Please refer to the individual ingredient package inserts or product-specific documentation for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The compound lacks a DrugBank ID, an approved indication, a confirmed mechanism of action, and any TxGNN-generated repurposing candidate. Without these anchors, neither computational nor evidence-based evaluation can proceed. The multi-ingredient homeopathic composition further complicates standard pharmacological analysis, as individual components act at sub-pharmacological dilutions under homeopathic convention and do not map cleanly to conventional drug–target relationships.

**To proceed, the following is needed:**

- **Identity resolution**: Determine whether this compound corresponds to a registered homeopathic product with an NDA or ANDA number (e.g., via FDA's homeopathic OTC monograph database or HPUS listing). If yes, retrieve the product-level DrugBank or RxNorm ID.
- **Indication clarification**: Confirm the original intended indication(s) from product labeling or manufacturer documentation.
- **MOA documentation**: For any ingredients with known pharmacological activity at conventional doses (e.g., activated charcoal for GI adsorption, cysteine as a mucolytic precursor, platinum compounds for cytotoxicity), provide compound-level evidence distinguishing pharmacological from homeopathic use.
- **Re-run pipeline**: Once a DrugBank ID and indication are confirmed, re-submit to the TxGNN pipeline with corrected metadata.
- **Regulatory pathway check**: If this is intended as a homeopathic OTC, assess applicability under FDA's 2019 Homeopathic Drug Products Guidance rather than the standard NDA repurposing pathway.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

